Cholesterol-modified oligonucleotides show promise for treating brain diseases

Getting therapeutic drugs past the blood-brain barrier has long been one of medicine's most difficult challenges, limiting our ability to treat conditions like Alzheimer's disease, Parkinson's disease, and brain cancers. While manipulating gene expression in brain cells holds tremendous promise for treating these conditions, effectively delivering gene-targeting drugs to the brain has remained an elusive goal.